{
    "clinical_study": {
        "@rank": "156329", 
        "arm_group": [
            {
                "arm_group_label": "Observation", 
                "arm_group_type": "No Intervention", 
                "description": "subject only got observation"
            }, 
            {
                "arm_group_label": "Drug", 
                "arm_group_type": "Experimental", 
                "description": "subject were treated with Yallaferon\u00ae\uff0c the recombinant human interferon \u03b1-2b gel"
            }
        ], 
        "brief_summary": {
            "textblock": "to assess the efficacy and safety of recombinant human interferon \u03b1-2b gel (Yallaferon\u00ae) for\n      the treatment of patients with cervical high-risk HPV infections; to analyze the HPV type\n      infections and clinical negative conversion.\n\n      285 patients with positive high risk HPV infection were randomized into interferon gel group\n      and control group at ratio of 2:1 (203 patients in treatment group and 82 patients in\n      control group). The patients in treatment group received 1g recombinant human \u03b1-2b\n      interferon gel every other day for consecutive 3 courses of treatment, whereas no treatment\n      was conducted in control group."
        }, 
        "brief_title": "Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "HPV Infection", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 30 to 65 years of age the sex life of female patients;\n\n          2. , liquid-based cytology (TCT) check no intraepithelial lesions and malignant cells;\n\n          3. , HPV DNA typing test for high-risk HPV positive (including a single high-risk type\n             positive, and more high-risk type of positive and high-and low-risk hybrid positive).\n\n        15 kinds of high-risk types, including HPV16, 18,31,33,35,39,45,51,52,53,56,58,59,66,68\n\n        Exclusion Criteria:\n\n          -  (1) cervical intraepithelial neoplasia (CIN); (2), combined with a severe fungal,\n             trichomonas vaginitis; (3), severe primary diseases associated with cardiovascular,\n             liver, kidney and hematopoietic system; (4), allergies or allergy to the drug known\n             ingredients. (5), within 30 days to accept other clinical trials of drugs or are\n             participating in clinical trials; (6), pregnant and lactating women and to be\n             pregnant women; (7), the researchers do not consider it appropriate clinical trials."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "325", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01824992", 
            "org_study_id": "LeesPharm_RHI", 
            "secondary_id": "China State FDA"
        }, 
        "intervention": {
            "arm_group_label": "Drug", 
            "intervention_name": "Yallaferon\u00ae", 
            "intervention_type": "Drug", 
            "other_name": "Yallaferon\u00ae\uff0c the recombinant human interferon \u03b1-2b gel"
        }, 
        "intervention_browse": {
            "mesh_term": "Interferons"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 4, 2013", 
        "number_of_arms": "2", 
        "official_title": "a Multi-sites, Randomized, Parallel, Controlled Clinical Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon\u00ae) in HPV Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Primary efficacy endpoint was the difference of hr-HPV DNA negative conversion rate on the 6th month between the two groups.", 
            "measure": "difference of hr-HPV DNA negative conversion rate", 
            "safety_issue": "No", 
            "time_frame": "six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01824992"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary efficacy endpoints were the differences of single-type HPV infection, dual infection and multiple infections on the 6th month between the two groups.\nEvaluation criteria:\nNegative conversion was defined as all positive hr-HPV DNA at baseline turning negative.\nNon-negative conversion was defined as at least one of the positive hr-HPV DNA at baseline not turning negative.", 
            "measure": "Secondary efficacy endpoints were the differences of single-type HPV infection, dual infection and multiple infections on the 6th month between the two groups.", 
            "safety_issue": "No", 
            "time_frame": "six months"
        }, 
        "source": "Lee's Pharmaceutical Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lee's Pharmaceutical Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}